By Elizabeth Lopatto and Molly Peterson June 8 (Bloomberg) — Novartis AG ’s drug Gilenia has risks that may outweigh its benefit in treating multiple sclerosis, according to U.S. regulators reviewing whether to approve the first pill to slow progression of the disease. Gilenia, while effective, causes a gradual decline in lung function and is linked to certain cancers, Food and Drug Administration staff said in a review today. Outside advisers to the FDA will meet June 10 to recommend whether the drug, also called fingolimod , should be approved for sale. Novartis, of Basel, Switzerland, is racing German drugmaker Merck KGaA to sell the first pill to stall MS, competing with injected remedies led by Biogen Idec Inc.’s Avonex. The FDA has said it will complete its review by September. Gilenia may go on sale in 2010 and reap $1 billion a year, Novartis has said. “The pivotal efficacy studies provide robust evidence of the efficacy of fingolimod to reduce the frequency of clinical exacerbations in patients with relapsing remitting MS,” FDA staff said in the report. “The clinical development program also uncovered a number of safety issues, which will be the primary focus for the advisory committee meeting.” Skin cancer and heart risks will probably fuel a “vigorous debate” at the panel meeting, Yaron Werber , an analyst for Citibank in New York, said June 4 in a research note. Those risks were linked to the treatment in a study published in January in the New England Journal of Medicine, and also identified as adverse events in the FDA review today. Novartis fell 35 centimes, or 0.7 percent, to 52.05 Swiss francs at 2:35 p.m. local time in Zurich trading. More Information The FDA may ask for more information on Gilenia in September instead of clearing it, a move that would delay approval until the end of 2011, Werber said. “A positive recommendation is far from certain and, even if the panel does give a positive vote, the FDA’s recent track record has become somewhat less predictable,” Werber said. Global sales of Gilenia may reach $780 million in 2014, he said. The FDA rejected Merck’s application for rival pill cladribine in November, saying it was incomplete. Merck, based in Darmstadt, Germany, said today it resubmitted the drug for U.S. approval. Multiple sclerosis affects about 2.5 million people, according to the National Multiple Sclerosis Society in the U.S., causing the body to attack itself through the immune system. Immune System Gilenia and cladribine both blunt the immune system’s attack on nerve cells. Cladribine was approved more than a decade ago to fight leukemia; both it and Gilenia target certain white blood cells that are part of multiple sclerosis’s attack on the protective coating of nerve cells. Acorda Therapeutics Inc. ’s pill to improve walking in multiple sclerosis patients was approved by U.S. regulators in January, the first therapy of its kind cleared for sale. The pill, which is co-promoted with Biogen, doesn’t treat the underlying disease. Doctors also often prescribe oral corticosteroids to damp the immune system’s effects during acute attacks; they don’t affect the underlying disease either. Novartis and Mitsubishi Tanabe Pharma Corp. will develop and sell fingolimod together in Japan, said Takayuki Ikeda, a spokesman for the Osaka-based drugmaker. Novartis bought overseas rights in September 1997 to the medicine, discovered in research involving Mitsubishi Tanabe’s predecessor company, Ikeda said. To contact the reporter on this story: Elizabeth Lopatto in New York at elopatto@bloomberg.net ; Molly Peterson in Washington at mpeterson9@bloomberg.net
Go here to see the original:
Novartis MS Pill’s Risks May Outweigh Benefits as FDA Advisers Review Drug






